MAP3K1 and lung carcinoma: MDA-MB-468 breast cancer, H358 lung cancer and HCT116 colon cancer cells in which MAP3K1 or MAP2K4 was knocked out all show a marked increase in sensitivity to selumetinib (Fig. 2a–c).